Paradigm Biopharmaceuticals Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: -3.276x

Paradigm Biopharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) has a cash flow conversion efficiency ratio of -3.276x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-19.65 Million ≈ $-13.90 Million USD) by net assets (AU$6.00 Million ≈ $4.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Paradigm Biopharmaceuticals Ltd (2014–2025)

Cash flow conversion efficiency of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. This chart illustrates how Paradigm Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Paradigm Biopharmaceuticals Ltd for real-time trading data and today's change.

Paradigm Biopharmaceuticals Ltd Cash Flow Conversion Ratio Explained

Paradigm Biopharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Paradigm Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Paradigm Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see Paradigm Biopharmaceuticals Ltd (PAR) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Net Insight AB (publ) ST:NETI-B	0.068x
Sambo Corrugated Board Co. Ltd KQ:023600	0.024x
Aifeex Nexus Acquisition Corporation NASDAQ:AIFE	-0.002x
Star Holdings NASDAQ:STHO	-0.030x
The Platform Group AG XETRA:TPG	0.113x
Brii Biosciences Limited F:7SS	N/A
Softstar Entertainment TWO:6111	-0.024x
Red Star Macalline Group Corporation Ltd F:3S5	-0.008x

Annual Cash Flow Conversion Efficiency for Paradigm Biopharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. Review Paradigm Biopharmaceuticals Ltd leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$21.18 Million ≈ $14.99 Million	AU$-15.99 Million ≈ $-11.32 Million	-0.755x	+72.75%
2024-06-30	AU$23.81 Million ≈ $16.84 Million	AU$-65.94 Million ≈ $-46.66 Million	-2.770x	-229.06%
2023-06-30	AU$53.68 Million ≈ $37.98 Million	AU$-45.19 Million ≈ $-31.97 Million	-0.842x	-10.60%
2022-06-30	AU$42.31 Million ≈ $29.94 Million	AU$-32.21 Million ≈ $-22.79 Million	-0.761x	-70.56%
2021-06-30	AU$78.27 Million ≈ $55.38 Million	AU$-34.93 Million ≈ $-24.71 Million	-0.446x	-378.45%
2020-06-30	AU$108.18 Million ≈ $76.55 Million	AU$-10.09 Million ≈ $-7.14 Million	-0.093x	-21.34%
2019-06-30	AU$82.81 Million ≈ $58.59 Million	AU$-6.37 Million ≈ $-4.50 Million	-0.077x	+82.28%
2018-06-30	AU$13.86 Million ≈ $9.81 Million	AU$-6.01 Million ≈ $-4.25 Million	-0.434x	-29.92%
2017-06-30	AU$13.39 Million ≈ $9.47 Million	AU$-4.47 Million ≈ $-3.16 Million	-0.334x	-4.51%
2016-06-30	AU$11.23 Million ≈ $7.95 Million	AU$-3.59 Million ≈ $-2.54 Million	-0.319x	-284.01%
2015-06-30	AU$14.46 Million ≈ $10.23 Million	AU$-1.20 Million ≈ $-851.40K	-0.083x	-102.05%
2014-06-30	AU$-151.87K ≈ $-107.45K	AU$-617.72K ≈ $-437.08K	4.068x	--

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology

Market Cap

$91.09 Million

AU$128.74 Million AUD

Market Cap Rank

#19321 Global

#619 in Australia

Share Price

AU$0.25

Change (1 day)

+0.00%

52-Week Range

AU$0.14 - AU$0.39

All Time High

AU$4.35